Biorek develops screening, diagnosis, and prognosis solutions to diagnose kidney cancer with a liquid biopsy. Its diagnostic solutions for renal cell carcinoma are based on molecular biomarkers deriving from liquid biopsies (whole blood and urine). These solutions help to detect the presence of a kidney mass in a patient and also discriminate between patients with a malignant lesion and patients with a benign group to determine the aggressiveness of renal cell carcinoma.